Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer

Summary

This study is an open-label, multicenter, umbrella study aimed to evaluate the combined, biomarker-driven, targeted treatment efficiency of Pamiparib, Bevacizumab, Tislelizumab, and Nab-paclitaxel in patients with platinum-resistant recurrent ovarian cancer (PROC).

Conditions

• Ovarian Cancer

Interventions

DRUG

Pamiparib

40mg PO. bid.

DRUG

Bevacizumab

7.5mg/kg IV. D1 (q3w.)

DRUG

Tislelizumab

200mg IV. D1

DRUG

Nab paclitaxel

125mg / m2 IV. D1, 8 (q3w).

DRUG

Bevacizumab + Nab paclitaxel (intense dose-dense)

Bevacizumab 7.5mg/kg IV. D1, 15 (Q4w). + Nab paclitaxel 100mg / m2 IV. D1, 8, 15 (Q4w).

Sponsors & Collaborators

• Hubei Cancer Hospital

  collaborator OTHER

• Union Hospital, Tongji Medical College

  collaborator UNKNOWN

• Peking University Cancer Hospital & Institute

  collaborator OTHER

• Anhui Provincial Hospital

  collaborator OTHER_GOV

• Sun Yat-sen University Cancer Center (SUSUCC)

  collaborator UNKNOWN

• Shandong Cancer Hospital and Institute

  collaborator OTHER

• The First Affiliated Hospital of Xi 'an Jiaotong University

  collaborator UNKNOWN

• Fujian Cancer Hospital

  collaborator OTHER_GOV

• Chongqing University Cancer Hospital

  collaborator OTHER

• Qilu Hospital of Shandong University

  collaborator OTHER

• Tongji Hospital

  lead OTHER

Principal Investigators

• Qinglei Gao, MD. PhD · Tongji Hospital

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

FEMALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-07-22

Primary Completion

2025-02-17

Completion

2025-02-17

Countries

• China

Study Locations